Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

ISSUE: Teva Pharmaceuticals USA, Inc. (Teva) initiated a voluntary recall to retail-level on 05/31/2017 for one lot of Paliperidone Extended-Release Tablets, 3mg, 90 count bottles, lot 1160682A, expiration 6/2018, NDC 0591-3693-19, that was distributed under the Actavis Pharma Inc. label. In coordination with FDA, Teva is extending this recall to the consumer/user level. 

This recall is being carried out due to failing test results for dissolution. Teva cannot at this time exclude the potential for additional tablets to be below specification.

Taking a product for the treatment of schizophrenia and schizoaffective disorders that has failed dissolution could result in less drug being absorbed. If two or more consecutive dosing regimens are with affected product, a failure to maintain therapeutic levels could occur, which could reduce effectiveness in treating a patient’s mental and/or mood symptoms, including suicidal thoughts and behavior, self-injurious behavior, mental hospitalizations, assaults, aggressive behavior, as well as vocal and motor tics. 

Based on Teva’s investigation, the likelihood of consuming two or more consecutive doses with affected product is low.  In addition, no post marketing adverse events have been received to date for lack of effectiveness for this recalled lot.

BACKGROUND: Paliperidone Extended Release Tablets, 3mg is indicated for the treatment of schizophrenia and schizoaffective disorders and was distributed nationwide in the USA to wholesalers.

RECOMMENDATION: Teva has issued an Ur...

Recommended for you

  • FDA Drug Updates
  • 1 comment

FDA approves Besponsa (inotuzumab ozogamicin) for acute lymphoblastic leukemia

Read more
  • MedWatch Drug Updates
  • 1 comment

Class I recall of Zenith Alpha Thoracic Endovascular Graft by Cook Medical – thrombus may form inside the device

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of lorazepam oral concentrate, USP 2mg/mL - defect in the dropper markings

Read more
  • FDA Drug Updates
  • 1 comment

New targeted treatment approved for relapsed or refractory acute myeloid leukemia

Read more
  • MedWatch Drug Updates
  • no comment

FDA safety alert: Potential complication associated with liquid-filled intragastric balloon systems

Read more
  • MedWatch Drug Updates
  • no comment

FDA Alert: Lack of sterility assurance for sterile drug products from Vital Rx, dba Atlantic Pharmacy and Compounding

Read more
  • MedWatch Drug Updates
  • no comment

Recall of all liquid products manufactured by PharmaTech: Risk of product contamination

Read more
  • MedWatch Drug Updates
  • no comment

Recall of pravastatin sodium tablets by International Laboratories: Mislabeled and contained different drug

Read more
  • MedWatch Drug Updates
  • no comment

Class I recall of Penumbra 3D Revascularization device by Penumbra: delivery wire may break or separate during use

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for Hepatitis C

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Nerlynx (neratinib) for breast cancer

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA advise not to use any liquid product manufactured by PharmaTech due to possible contamination

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA warning against the use of Balguti Kesaria Ayurvedic Medicine due to risk of lead poisoning

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA Investigation: Hypersensitivity reaction due to ungraded ingredient in curcumin emulsion for Injection by ImprimisRx

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Endari (L-glutamine) for sickle cell disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Novopen Echo Insulin Delivery Device by Novo Nordisk: Chemical exposure may damage cartridge holder

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Atar Extension Cables by Oscor- cable malfunction interrupting the pacing system

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Diocto Liquid and Diocto Syrup by Rugby Laboratories: Risk of product contamination

Read more
  • FDA Drug Updates
  • 1 comment

FDA expands approved use of Imbruvica (ibrutinib) for chronic graft versus host disease

Read more
  • MedWatch Drug Updates
  • 1 comment

Safety alert against compounded triamicinolone and moxifloxacin intravitreal Inj by Guardian Pharmacy Services

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of cyclobenzaprine and amantadine by Apace Packaging due to a potential mislabeling

Read more
  • FDA Drug Updates
  • 1 comment

FDA approved Haegarda (C1 esterase inhibitor) for Hereditary Angioedema

Read more
  • MedWatch Drug Updates
  • 1 comment

Field Correction of system CS100, CS100i and CS300 Intra-Aortic Balloon Pumps by Datascope

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Clindamycin Injection USP ADD-Vantage vials by Alvogen: Presence of microbial growth

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Nitroglycerin Injection in 5% Dextrose USP by Advanced Pharma due to sub-potency

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of Paliperidone Extended-Release tablets, 3mg by Teva Pharmaceuticals due to failure of dissolution test

Read more
  • MedWatch Drug Updates
  • 1 comment

FDA safety alert: Navigational accuracy errors associated with frameless stereotaxic navigation systems

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of one lot Eliquis 5 mg tablets by Bristol-Myers Squibb- Contain product of incorrect strength

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of topical products by Phillips Company- Improper manufacturing practices affecting product's quality

Read more
  • MedWatch Drug Updates
  • 1 comment

Recall of La Bri's Body Health Atomic and Xplode capsules by EZ Weight Loss TX: Contain banned drug sibutramine

Read more